| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424224100 | Rhabdoviridae (e.g., rabies virus, vesicular stomatitis virus, etc.) | 17 |
| 20080206282 | Chimeric lyssavirus nucleic acids and polypeptides - The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules. | 08-28-2008 |
| 20100189746 | ADAPTATION OF PITMAN MOORE STRAIN OF RABIES VIRUS TO PRIMARY CHICK EMBRYO FIBROBLAST CELL CULTURES - The present invention relates to a process of adaptation of Pitman Moore strain of rabies virus to Primary chick fibroblast cells for the production of rabies vaccine. | 07-29-2010 |
| 20100260798 | Method for purifying the rabies virus - The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which:
| 10-14-2010 |
| 20100278864 | Rabies Vaccine - An attenuated rabies virus for use as a live vaccine. The attenuated rabies virus expresses an immune factor that enhances immune response upon administration of the live vaccine. | 11-04-2010 |
| 20100297176 | Polyinosinic Acid - Polycytidylic Acid - Based Adjuvant - The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with an antigen (e.g., as in a vaccine). The adjuvant compositions of the invention have particular physical properties (e.g., molecular weight, concentration, and pH) which address the need for a safe adjuvant for eliciting an enhanced immune response. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response to an antigenic compound. | 11-25-2010 |
| 20110070264 | RABIES VIRUS VECTOR SYSTEMS AND COMPOSITIONS AND METHODS THEREOF - Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus. | 03-24-2011 |
| 20110081380 | Stabilizing Excipient for Inactivated Whole Virus Vaccine - The invention relates to a vaccine composition comprising:
| 04-07-2011 |
| 20120171246 | IMMUNIZATION TO REDUCE NEUROTOXICITY DURING TREATMENT WITH CYTOLYTIC VIRUSES - Methods for protecting the brain and other tissues from virus-associated toxicity are provided. Patients are treated with a first immunizing virus prior to administration of a second, therapeutic cytolytic virus. The immunizing virus is preferably administered peripherally, and initiates an adaptive immune response that is sufficient to reduce or prevent the cytovirulence and inflammation caused by the therapeutic virus. The immunizing virus is administered one or more times, preferably at least twice, before administration of the therapeutic virus. The therapeutic virus can be the same virus as the immunizing virus, or a mutant or variant thereof. Preferably the therapeutic virus is an attenuated virus with reduced virulence compared to the immunizing virus. | 07-05-2012 |
| 20130095137 | PAN-LYSSAVIRUS VACCINES AGAINST RABIES - Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another | 04-18-2013 |
| 20130177591 | Lipid Based Adjuvants for DNA Plasmids - The present invention provides for a novel vaccine formulation comprising plasmid DNA and a lipid adjuvant. The invention also provides for prime-boost vaccination methods wherein two sequential administration of the same plasmid-based DNA vaccine provide companion animals with protection against rabies for at least one year. | 07-11-2013 |
| 20130287812 | anti-HPV drug and its application in preparing medicines for treatment of HPV (human papilloma virus) infection - This invention disclosed an anti-HPV drug and its applications in preparing medicines for treatment of HPV (human papilloma virus) infection. This drug was characterized by using human rabies vaccine as its active ingredient and being produced by adding pharmacologically acceptable carriers. This invention also disclosed drug applications in preparing medicines for treatment of HPV infection, i.e. new applications of human rabies vaccines for preparing medicines against HPV infection. The anti-HPV drug described in this invention (i.e. human rabies vaccine) had obvious treatment effects on HPV infection. According to the animal tests and preclinical observation, this drug provided satisfactory and beneficial effects and had the characteristics of safety, effectiveness and nearly no recurrence after treatment; the negative-conversion rate in patients with positive HPV-infection reached 90% after treatment. | 10-31-2013 |
| 20140037684 | STABILIZING EXCIPIENT FOR INACTIVATED WHOLE VIRUS VACCINE - The invention relates to a vaccine composition comprising:
| 02-06-2014 |
| 20140178431 | LIPID AND NITROUS OXIDE COMBINATION AS ADJUVANT FOR THE ENHANCEMENT OF THE EFFICACY OF VACCINES - The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5ω3], decosahexaenoic acid [C22: 6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. | 06-26-2014 |
| 20140271716 | Intra-testicular Injection of Immunogens - A method for inducing an immune response by injecting an immunogen into a subject's testis. A composition for intra-testicular injection including an immunogen such as a rabies vaccine and a chemical sterilant formed of zinc gluconate and an amino acid capable of forming an aqueous solution neutralized to a pH from 6.0 to 7.5. When injected intra-testicularly, the immunogen is slowly released reducing or eliminating the need for a “booster” dose, while the chemical sterilant is effective at reducing the dog population. | 09-18-2014 |
| 20150030630 | ADJUVANTED FORMULATIONS OF RABIES VIRUS IMMUNOGENS - The efficacy of rabies vaccines can be enhanced by adjuvanting rabies virus immunogens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. The rabies virus immunogen can also be adsorbed to the metal salt. | 01-29-2015 |
| 20160089430 | COMPOSITIONS CONTAINING AMBIENT-TEMPERATURE STABLE, INACTIVATED BUT THERAPEUTICALLY ACTIVE BIOPHARMACEUTICALS & METHODS FOR FORMULATION THEREOF - The disclosure concerns compositions containing inactivated but therapeutically active biopharmaceuticals, and methods for formulation thereof. Biopharmaceuticals are encapsulated and immobilized in dry amorphous carbohydrate-glass and irradiated for inactivation while in the dry state. The resulting compositions provide ambient-temperature stable, therapeutically active but inactivated biopharmaceuticals for use in vaccines and other applications. | 03-31-2016 |
| 20160137700 | PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION AND PREPARATION METHOD AND USE THEREOF - Provided in embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic peptide vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs. | 05-19-2016 |
